PKC-β activation promotes obesity and metabolic dysfunction, while PKC-β deficiency or inhibition protects against weight gain, insulin resistance, and hepatic steatosis. Instacare Therapeutics has developed novel strategies to inhibit PKC-β in both systemic and tissue-specific manners.